ALNY Financial Performance
Use the table below to view Alnylam Pharmaceuticals, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements.
All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.
Based on Financial Statements from Q3 - 2024
| Metric | Value | Ranking among Peers |
|---|---|---|
| Price | $246.27 | - |
| 52 Week Low | $141.98 | - |
| 52 Week High | $304.39 | - |
| Market Cap | $31.8 Billion | 2/18 |
| Gross Margin | 99% | 3/18 |
| Profit Margin | -27% | 12/18 |
| EBITDA margin | -18% | 9/18 |
| Q3 - 2024 Revenue | $420.1 Million | 6/18 |
| Q3 - 2024 Earnings | -$111.6 Million | 15/18 |
| Q3 - 2024 Free Cash Flow | $39.5 Million | 7/18 |
| Trailing 4 Quarters Revenue | $2.0 Billion | 6/18 |
| Trailing 4 Quarters Earnings | -$332.3 Million | 14/18 |
| Quarterly Earnings Growth | -176% | 17/18 |
| Annual Earnings Growth | 51% | 5/18 |
| Quarterly Revenue Growth | -44% | 16/18 |
| Annual Revenue Growth | 18% | 6/18 |
| Cash On Hand | $1.1 Billion | 4/18 |
| Short Term Debt | $42.1 Million | 3/18 |
| Long Term Debt | $1.3 Billion | 3/18 |